Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Jordana B. Cohen(University of Pennsylvania), Julio A. Chirinos(The Lundquist Institute), Daniel Edmonston(Duke University), Alejandro Barbagelata(Favaloro Foundation), C. Medina(Hospital Nacional Cayetano Heredia), Luis E Bendezú-Huasasquiche, Tara I. Chang, Luz Alicia González-Hernández(Hospital Civil de Guadalajara), Tiffany Sharkoski(Hospital of the University of Pennsylvania), Preethi William(University of Arizona), Nelson R. Rosado‐Santander(Hospital Nacional Cayetano Heredia), Renzo Valdivia-Vega(Hospital Nacional Cayetano Heredia), Carlos Augusto Castro‐Callirgos(Instituto Nacional de Salud del Niño), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Jesse Chittams, Nicolás Renna(University of Mendoza), Eduardo F Bernales-Salas(Hospital Nacional Cayetano Heredia), James Brian Byrd(University of Michigan), Juan E. Rodriguez‐Mori(Instituto Nacional de Salud del Niño), Roberto Cristodulo-Cortez(Universidad Privada de Santa Cruz de la Sierra), Cynthia Daniela Salinas Herrera(Hospital Nacional Cayetano Heredia), Omar A Díaz-Cucho, Jonas Spaak(Karolinska University Hospital), Johanna C Coacalla-Guerra(Hospital Nacional Cayetano Heredia), Nancy K. Sweitzer(National Heart Lung and Blood Institute), Vicente Corrales‐Medina(University of Ottawa), Mauro Basconcel, Ricardo Ayala(Hospital Nacional Cayetano Heredia), Carlos E. Alfonso(University of Miami), Liliana Nicolosi, Thomas C. Hanff(University of Pennsylvania), Charles R. Vasquez(Hospital of the University of Pennsylvania), Mirko Villavicencio-Carranza(Hospital Nacional Cayetano Heredia)
The Lancet Respiratory Medicine
January 10, 2021
Cited by 224


Related Papers